The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
Open accessAbstract
BACKGROUND: The delivery of antipseudomonal antibiotics by inhalation to Pseudomonas aeruginosa-infected subjects with non-cystic fibrosis (CF) bronchiectasis is a logical extension of treatment strategies successfully developed in CF bronchiectasis. Dual release ciprofloxacin for inhalation (DRCFI) contains liposomal ciprofloxacin, formulated to optimise airway antibiotic delivery. METHODS: Phase II, 24-week Australian/New Zealand multicentre, randomised, double-blind, placebo-controlled trial in 42 adult bronchiectasis subjects with ≥2 pulmonary exacerbations in the prior 12 months and ciprofloxacin-sensitive P aeruginosa at screening. Subjects received DRCFI or placebo in three treatment cycles of 28 days on/28 days off. The primary outcome was change in sputum P aeruginosa bacterial density to the end of treatment cycle 1 (day 28), analysed by modified intention to treat (mITT). Key secondary outcomes included safety and time to first pulmonary exacerbation-after reaching the pulmonary exacerbation endpoint subjects discontinued study drug although remained in the study. RESULTS: DRCFI resulted in a mean (SD) 4.2 (3.7) log10 CFU/g reduction in P aeruginosa bacterial density at day 28 (vs -0.08 (3.8) with placebo, p=0.002). DRCFI treatment delayed time to first pulmonary exacerbation (median 134 vs 58 days, p=0.057 mITT, p=0.046 per protocol). DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group, but fewer pulmonary adverse events. CONCLUSIONS: Once-daily inhaled DRCFI demonstrated potent antipseudomonal microbiological efficacy in adults with non-CF bronchiectasis and ciprofloxacin-sensitive P aeruginosa. In this modest-sized phase II study, DRCFI was also well tolerated and delayed time to first pulmonary exacerbation in the per protocol population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, C., Jayaram, L., Karalus, N., Eaton, T., Tong, C., Hockey, H., Milne, D., Fergusson, W., Tuffery, C., Sexton, P., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60953-2 · Cited by 600
Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection
Wong, J. P., Yang, H., Blasetti, K. L., Schnell, G., Conley, J., & Schofield, L. N. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00358-4 · Cited by 153
Cited by
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
European Respiratory Society guidelines for the management of adult bronchiectasis
Polverino, E., Goeminne, P. C., McDonnell, M. J., Aliberti, S., Marshall, S. E., Loebinger, M. R., Murris, M., Cantón, R., Torres, A., Dimakou, K., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00629-2017 · Cited by 1,333
Self-citationBritish Thoracic Society Guideline for bronchiectasis in adults
T Hill, A., L Sullivan, A., D Chalmers, J., De Soyza, A., Stuart Elborn, J., Andres Floto, R., Grillo, L., Gruffydd-Jones, K., Harvey, A., S Haworth, C., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212463 · Cited by 617
Self-citationPulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research
Hill, A. T., Haworth, C. S., Aliberti, S., Barker, A., Blasi, F., Boersma, W., Chalmers, J. D., De Soyza, A., Dimakou, K., Elborn, J. S., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00051-2017 · Cited by 439
Self-citationDelivery strategies for sustained drug release in the lungs
Loira-Pastoriza, C., Todoroff, J., & Vanbever, R. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.017 · Cited by 393
Metadata
- Authors
- Serisier, D. J., Bilton, D., De Soyza, A., Thompson, P. J., Kolbe, J., Greville, H. W., Cipolla, D., Bruinenberg, P., Gonda, I., & the ORBIT-2 investigators
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2013-05-16
- Volume
- 68
- Issue
- 9
- Pages
- 812-817
- ISSN
- 0040-6376 (ISSN-L)
- 1468-3296
- OpenAlex
- W2161605184
- Cited by
- 250
- References
- 2
- FWCI
- 23.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1136/thoraxjnl-2013-203207
- The paper
- Serisier, D. J., Bilton, D., De Soyza, A., Thompson, P. J., Kolbe, J., Greville, H. W., Cipolla, D., Bruinenberg, P., Gonda, I., & the ORBIT-2 investigators. (2013). Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. https://doi.org/10.1136/thoraxjnl-2013-203207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.